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The present issue of Neuro-Oncology Practice has a focus on gliomas and challenges in the 
diagnoses and treatment of brain metastasis. An invited review by Dr. Kruchko and 
colleagues for the Central Brain Tumor Registry of the United States summarizes efforts to 
improve the collection of data on central nervous system tumor within CBTRUS, notably the 
integration of molecular markers. The latter became necessary based on the revised WHO 
classification of brain tumors which makes limited molecular testing almost mandatory for 
certain disease entities, notably gliomas of adulthood. Incorporating molecular data will 
greatly increase the value of this resource for clinical research in brain tumors.  
Several further articles focus on exploring the value of novel treatment approaches for brain 
tumors in adults. Nakajima and colleagues report that awake surgery for patients with 
gliomas usually had a good functional outcome at their site, but that deep sensory function 
and visual spatial cognition were domains most likely to be affected. The tolerability and 
efficacy of hypofractionated stereotactic radiotherapy for intracranial meningiomas was 
studied in a systematic review that was conducted by Nguyen and colleagues. They arrive at 
the conclusion that local control and tolerability of hypofractionated stereotactic radiotherapy 
are comparable to traditionally used other radiation regimens. Re-irradiation for recurrent 
glioblastoma remains a widely used treatment modality although its efficacy has not been 
demonstrated in a randomized clinical trial. Chapman and colleagues report that prognostic 
factors for overall survival in patients undergoing re-irradiation were age, time to initial 
progression and planning target volume. While these data may help to derive prognostic 
information, these prognostic factors are not surprising and might be reproduced when using 
other treatment modalities. With improved outcomes for glioma patients, the quality of 
survival becomes an increasingly important consideration. Ability to return to work is in fact a 
relevant outcome measure when assessing impact of therapeutic interventions. In that 
regard, Altshuler and colleagues report that polymorphisms in the BDNF, COMT and DRD2 
genes, which have previously been associated with higher performance in neurocognitive 
domains in aging and other diseases, were also associated with higher likelihood to return to 
work in patients with gliomas. Finally, Kim and colleagues identified a group of 155 patients 
who survived glioblastoma for more than five years. They observed 17 secondary cancers in 
13 of these patients. These observations illustrate the necessity for comprehensive 
oncological follow-up in long-term survivors of glioblastoma. 
The last three publications address current issues in the diagnosis and treatment of brain 
metastasis. Fares and colleagues have compiled an interesting review on clinical trials 
conducted in patients with brain metastasis from breast cancer. There is overall a low 
number of trials and accrual seems to be challenging. Many trials appear not to reach the 
state of publication. Pathways to improve the current situation are discussed. Given the 
improved outcome from patients with metastatic melanoma or lung cancer even with brain 
metastasis since the introduction of immunotherapy, the role and optimal timing of 
radiosurgery is increasingly being challenged. There are strong opinions favoring either early 
or delayed radiosurgery, but there are no data from controlled clinical trials. Lanier et al., 
reviewing their patients retrospectively, arrive at the conclusion that the combination of 
immunotherapy with stereotactic radiosurgery improves outcome but randomized trials 
remain necessary to confirm this conclusion. Finally, Anderson and colleagues report on their 
own algorithm how to manage neurological complications in patients treated with immune 
checkpoint inhibitors. The majority of these complications is related to the peripheral nervous 
system and mimick myasthenia gravis or Guillain-Barré syndrome. Treatment algorithms like 
the one proposed here will assume an increasing importance, but need to be evaluated and 
optimized in a prospective fashion. 
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